-
Three-year follow-up of rheumatoid meningitis with matrix metalloprotease-9 levels in the serum and cerebrospinal fluid as indicators of disease activity: A case report J. Neuroimmunol. (IF 3.3) Pub Date : 2024-03-16 Keishu Murakami, Katsuichi Miyamoto, Jinsoo Koh, Yoshinori Kajimoto, Hidefumi Ito
Rheumatoid meningitis (RM) is an extra-articular complication of rheumatoid arthritis (RA). Although reports of RM sine arthritis exist, most patients with this presentation were diagnosed with RA within one year of RM onset. There are no established biomarkers reflecting the disease activity of RM. This case report highlights the elevation of matrix metalloprotease (MMP)-9 levels during the acute
-
Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series J. Neuroimmunol. (IF 3.3) Pub Date : 2024-03-14 Edward H. Chang, Todd A. Hardy
Siponimod is a sphingosine 1-phosphate receptor (S1P) modulator used to treat secondary progressive multiple sclerosis (SPMS). We report 3 SPMS patients treated with siponimod who developed new or worsening peripheral oedema soon after commencing treatment. In one case, peripheral oedema resulted in immobility. Siponimod-related peripheral oedema deserves wider recognition due to the potential for
-
Mycobacterial spindle cell pseudotumor of the spinal cord: Case report and literature review J. Neuroimmunol. (IF 3.3) Pub Date : 2024-03-12 Michael Tran Duong, Adam Ungemach, Faizan Malik, Melissa T. Duong, Noah Wasserman, Kumarasen Cooper, Austin R. Pantel, Jessica O'Neil, Zsofia Szep
We report the first description of spinal cord mycobacterial spindle cell pseudotumor. A patient with newly diagnosed advanced HIV presented with recent-onset bilateral leg weakness and was found to have a hypermetabolic spinal cord mass on structural and molecular imaging. Biopsy and cultures from blood and cerebrospinal fluid confirmed spindle cell pseudotumor due to . Despite control of HIV and
-
Novel biomarkers and interferon signature in secondary progressive multiple sclerosis J. Neuroimmunol. (IF 3.3) Pub Date : 2024-03-06 Avital Fogel, Maya Olcer, Aika Goel, Xuan Feng, Anthony T. Reder
Multiple sclerosis (MS) exhibits poor immune regulation and subnormal interferon (IFN-β) signaling. Secondary Progressive MS displays waning exacerbations, relentless neurodegeneration, and diminished benefit of therapy. We find dysregulated serum protein balance (Th1/Th2) and excessive gene expression in Relapsing-Remitting MS vs. healthy controls (8700 differentially-expressed genes, DEG) and intermediate
-
Follow-up of cognitive impairment and inflammatory profile in individuals with mild COVID-19 J. Neuroimmunol. (IF 3.3) Pub Date : 2024-03-05 Nathália Gualberto Souza-Silva, Daniela Valadão Rosa, Jonas Jardim de Paula, Roney Santos Coimbra, Débora Marques Miranda, Marco Aurélio Romano-Silva
Individuals who experience mild COVID-19 can suffer from long-lasting cognitive symptoms. Notably, 26% of these individuals experience difficulties with visuospatial abilities six months after infection. However, among those who initially exhibited visuoconstructive impairments, 66% showed improvement or complete reversal over time. Additionally, changes in cytokine levels, particularly CCL11, HGF
-
Low-dose rituximab treatment in a patient with anti-neurofascin-155 IgG4 autoimmune nodopathy J. Neuroimmunol. (IF 3.3) Pub Date : 2024-02-27 Ivan Kmezic, Rayomand Press, Helena Glenewinkel, Kathrin Doppler, Luise Appeltshauser
Autoimmune nodopathy is a new entity of immune-mediated neuropathies associated with antibodies against nodal-paranodal epitopes. We present a detailed clinical and serological work-up of a patient with autoimmune nodopathy with anti-neurofascin-155 (anti-NF-155) IgG4 antibodies who was treated with low-dose (500 mg) rituximab, which led to a decrease of anti-NF-155 antibody titer, depletion of B cells
-
Immune and glial cell alterations in the rat brain after repeated exposure to the synthetic cannabinoid JWH-018 J. Neuroimmunol. (IF 3.3) Pub Date : 2024-02-26 Nicholas Pintori, Rafaela Mostallino, Enrica Spano, Valeria Orrù, Maria Grazia Piras, Maria Paola Castelli, Maria Antonietta De Luca
The use of synthetic cannabinoid receptor agonists (SCRAs) poses major psychiatric risks. We previously showed that repeated exposure to the prototypical SCRA JWH-018 induces alterations in dopamine (DA) transmission, abnormalities in the emotional state, and glial cell activation in the mesocorticolimbic DA circuits of rats. Despite growing evidence suggesting the relationship between substance use
-
Neuromodulator hydrogen sulfide attenuates sickness behavior induced by lipopolysaccharide J. Neuroimmunol. (IF 3.3) Pub Date : 2024-02-24 Merelym K. Oliveira, Tatiane H. Batista, Viviana Carolina T. Rojas, Fernando Vitor-Vieira, Letícia Reis, Fabiana Cardoso Vilela Giusti, Alexandre Giusti-Paiva
Sickness behavior reflects a state of altered physiology and central nervous system function that occurs during systemic infection or inflammation, serving as an adaptive response to illness. This study aims to elucidate the role of hydrogen sulfide (HS) in regulating sickness behavior and neuroinflammatory responses in a rat model of systemic inflammation. Adult male Wistar rats were treated with
-
The medulla oblongata shows a sex-specific inflammatory response to systemic neonatal lipopolysaccharide J. Neuroimmunol. (IF 3.3) Pub Date : 2024-02-17 Kateleen E. Hedley, Annalisa Cuskelly, Robert J. Callister, Jay C. Horvat, Deborah M. Hodgson, Melissa A. Tadros
-
Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis J. Neuroimmunol. (IF 3.3) Pub Date : 2024-02-17 Shitiz Sriwastava, Mahmoud Elkhooly, Suban Amatya, Kriti Shrestha, Yusuf Kagzi, Dipika Bhatia, Rajesh Gupta, Shruti Jaiswal, Robert P. Lisak
The article highlights upcoming potential treatments, which target different phases of inflammation and offer remyelinating strategies as well as direct and indirect neuroprotective and oligodendrocyte protective effects, providing a hopeful outlook for patients with primary and secondary progressive multiple sclerosis (PPMS and SPMS). The review aims to identify potential treatments and ongoing clinical
-
EBV infected cells in the multiple sclerosis brain express PD-L1: How the virus and its niche may escape immune surveillance J. Neuroimmunol. (IF 3.3) Pub Date : 2024-02-15 Barbara Serafini, Lucia Benincasa, Barbara Rosicarelli, Francesca Aloisi
The presence of EBV infected B cells in postmortem multiple sclerosis (MS) brain tissue suggests immune evasion strategies. Using immunohistochemical techniques we analysed the expression of the immune checkpoint molecule PD-L1 and its receptor PD-1 in MS brains containing B cell-enriched perivascular infiltrates and meningeal follicles, a major EBV reservoir. PD-1 and PD-L1 immunoreactivities were
-
Granagard administration prolongs the survival of human mesenchymal stem cells transplanted into a mouse model of multiple sclerosis J. Neuroimmunol. (IF 3.3) Pub Date : 2024-02-14 Kati Frid, Areen Usmann, Tsipora Markovits-Pachter, Orli Binyamin, Panayota Petrou, Ibrahim Kassis, Dimitri Karussis, Ruth Gabizon
The clinical effect of human Mesenchymal stem cells (hMSCs) transplanted into EAE mice/MS patients is short lived due to poor survival of the transplanted cells. Since Granagard, a nanoformulation of pomegranate seed oil, extended the presence of Neuronal Stem cells transplanted into CJD mice brains, we tested whether this safe food supplement can also elongate the survival of hMSCs transplanted into
-
-
In memoriam: Jennifer L. Stark, PhD J. Neuroimmunol. (IF 3.3) Pub Date : 2024-02-08 Laura Piccio, Anne H. Cross
-
Papillitis associated with IgLON5 autoimmunity: A novel clinical phenotype J. Neuroimmunol. (IF 3.3) Pub Date : 2024-02-05 Xiaoyang Li, John J. Chen, Minjun Hur, Gillian R. Paton, Andrew McKeon, Anastasia Zekeridou
To describe papillitis as a clinical phenotype of IgLON5 autoimmunity. We retrospectively reviewed patients with IgLON5 autoimmunity who had optic neuropathy, optic neuritis, or optic disc edema. Sera from patients with recurrent papillitis were tested for IgLON5 antibodies. We found two elderly males presenting with papillitis in the presence of IgLON5 antibodies. CSF pleocytosis was present and partial
-
Caveolin-1 mediates blood-brain barrier permeability, neuroinflammation, and cognitive impairment in SARS-CoV-2 infection J. Neuroimmunol. (IF 3.3) Pub Date : 2024-02-04 Troy N. Trevino, Ali A. Almousawi, KaReisha F. Robinson, Avital B. Fogel, Jake Class, Richard D. Minshall, Leon M. Tai, Justin M. Richner, Sarah E. Lutz
-
Expression of lymphocyte activation gene-3 on CD4+T cells is regulated by cytokine interleukin-18 in myasthenia gravis J. Neuroimmunol. (IF 3.3) Pub Date : 2024-02-02 Jingluan Tian, Xuan Liu, Hansi Liang, Yu Shen, Xuanyi Xiang, Feng Zhu, Xin Wang, Cuiping Liu, Xingshun Xu, Xueguang Zhang, Qun Xue, Yanzheng Gu
Myasthenia gravis (MG) is a T cell-dependent, B cell-mediated, and complement-dependent autoimmune disease. Lymphocyte activation gene-3 (LAG-3; CD223) is an immune checkpoint protein that plays an important role in maintaining autoimmune tolerance and homeostasis. To investigate the cytokine-regulated expression pattern of LAG-3, CD4T cells were sorted from the peripheral blood of healthy volunteers
-
Disease modifying therapy in the treatment of tumefactive multiple sclerosis: A retrospective cohort study J. Neuroimmunol. (IF 3.3) Pub Date : 2024-02-01 Kristin Galetta, Andrew Siyoon Ham, Anastasia Vishnevetsky, Shamik Bhattacharyya, Farrah J. Mateen
Tumefactive multiple sclerosis (TMS) is characterized by large demyelinating brain lesions. This was a retrospective cohort study of 67 patients with TMS between January 2015–2023, examining different disease modifying therapy impact on expanded disability scale score change at follow-up. Median age was 36 with a female predominance. Mean EDSS was 3.3 ± 2.3 at TMS onset, 2.1 ± 1.9 at year one, and
-
Time to FIRE NORSE: A single acronym for a heterogeneous presentation. Further information from a case series and discussion of the literature. J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-26 Abdulaziz M. Alaskar, Majed A. Aljohani, Sasha Dionisio, Mohammed A. Asiry, Khalid Alqadi
Purpose New-Onset Refractory Status Epilepticus (NORSE) is a rare and severe form of refractory status epilepticus without an apparent underlying cause at presentation or prior history of epilepsy. We aimed to describe the clinical features, etiology, treatment, and outcomes of NORSE in adults in a quaternary-level hospital in Saudi Arabia. Methodology In this retrospective cohort study, inclusion
-
Inhibition of repulsive guidance molecule-a ameliorates compromised blood–spinal cord barrier integrity associated with neuromyelitis optica in rats J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-28 Masataka Katsu, Misuzu Sekine-Tanaka, Masaharu Tanaka, Yasushi Horai, Airi Akatsuka, Misao Suga, Kazuhiro Kiyohara, Takuya Fujita, Atsushi Sasaki, Toshihide Yamashita
-
Therapeutic plasma exchange for neuromyelitis optica attacks: Evidence and challenges from a real-world cohort from Brazil J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-24 Guilherme Mello Ramos de Almeida, Roger Santana de Araujo, Bruno Batitucci Castrillo, Guilherme Diogo Silva, Ida Fortini, Marcia Rubia Rodrigues Gonçalves, Luiz Henrique Martins Castro, Nelson Hidekazu Tatsui, Tarso Adoni, Douglas Kazutoshi Sato, Samira Luísa Apóstolos-Pereira, Dagoberto Callegaro
Therapeutic plasma exchange (TPE) can improve disability recovery after neuromyelitis optica spectrum disease (NMOSD) attacks, but its effectiveness and safety in Latin-American patients with access barriers and diverse ethnicity is underexplored. We carried out a retrospective cohort study with NMOSD patients that underwent TPE. 84 NMOSD attacks in 68 patients were evaluated. Despite a median 25-day
-
Diagnostic signatures and immune cell infiltration characteristics in anti-GABABR encephalitis J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-24 Shan Qiao, Wen-Yu Zhang, Yun-Fang Xie, Hai-Yun Li, Cai-San Cui, Shu-Xin Tao, Tao Xin, Qi-Ji Liu
Purpose Anti-gamma-aminobutyric acid B receptor (GABABR) encephalitis is an uncommon form of autoimmune encephalitis associated with a poor prognosis and a high fatality rate. We aim to find diagnostic markers for anti- GABABR encephalitis as well as the effects of immune cell infiltration on this pathology. Methods For quantitative proteomic analysis, isobaric tags for relative and absolute quantitation
-
Cerebellar leptomeningeal enhancement: An imaging finding of rapidly progressive Purkinje cell cytoplasmic autoantibody type 1 paraneoplastic cerebellar syndrome J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-19 Smathorn Thakolwiboon, Jenny Linnoila, Sean J. Pittock, Divyanshu Dubey, Anastasia Zekeridou
Purkinje cell cytoplasmic autoantibody type 1 (PCA1), also known as anti-Yo, is a ‘high-risk’ paraneoplastic antibody, associated with rapidly progressive cerebellar syndrome. In patients with this syndrome, various MRI abnormalities have been documented, including atrophy in the cerebellum and brainstem, T2 hyperintensity in the brainstem and spinal cord, and cranial nerve enhancement. This report
-
Mycophenolate mofetil for the long-term treatment of HTLV-1 associated myelopathy: A case report J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-22 Marta Sanz, Sofia Chernet, John Shymansky, Alexandra Mandel, Alisha Chitrakar, Henry J. Kaminski, Pritha Ghosh, Natalia Soriano-Sarabia
-
Incident anti-LGI1 autoimmune encephalitis during dementia with Lewy bodies: when Occam razor is a double-edged sword J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-14 Denise Cerne, Mattia Losa, Pietro Mattioli, Anastasia Lechiara, Giacomo Rebella, Luca Roccatagliata, Dario Arnaldi, Angelo Schenone, Silvia Morbelli, Luana Benedetti, Federico Massa
-
Gamma-oryzanol attenuates lipopolysaccharide-induced cognitive impairment by modulation of hippocampal inflammatory response and glial activation in mice J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-18 Shiva Zeini, Nahid Davoodian, Seyed Abdollah Mousavi
-
Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-17 Nitsan Haham, Omri Zveik, Ariel Rechtman, Livnat Brill, Adi Vaknin-Dembinsky
Co-inhibitory receptors (CIR)s regulate T cell-mediated immune responses and growing evidence links co-inhibitory receptors to the progression of neuroimmunological diseases. We studied the expression levels of CIRs: TIM-3, TIGIT, PD-1 and LAG-3 in the peripheral blood mononuclear cells (PBMCs) of 30 patients with Neuromyelitis optica spectrum disorder (NMOSD), 11 Multiple sclerosis (MS) patients and
-
Association of peripheral immune activation with amyotrophic lateral sclerosis and Parkinson's disease: A systematic review and meta-analysis J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-12 Han Wang, Yi-Ti Liu, Yan-Ling Ren, Xiao-Yan Guo, Yi Wang
Background Recent studies have revealed the link between immune activation and neurodegenerative diseases. Methods By employing meta-analysis, we estimated the standardized mean difference (SMD) and their corresponding 95% confidence intervals (CIs) between the groups. Results According to the pre-set criteria, a total of 21 published articles including 2377 ALS patients and 1244 HCs, as well as 60
-
-
Effects of treadmill training on myelin proteomic markers and cerebellum morphology in a rat model of cuprizone-induced toxic demyelination J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-08 Alireza Lotfi, Maryam Abbasi, Nasrin Karami, Hadis Arghavanfar, Fatemeh Kazeminasab, Sara K. Rosenkranz
-
Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-08 Chengyi Zhang, Rui Liu, Bin Gao, Ting Li, Huabing Wang, Tian Song, Yuetao Ma, Wangshu Xu, Yun Liu, Xinghu Zhang, De-Cai Tian, Chunsheng Yang, Kaibin Shi
Background Rituximab effectively targets B cells and reduces relapses in neuromyelitis optica spectrum disorder (NMOSD). But the ideal dosage and treatment intervals remain unanswered. We aimed to assess the efficacy and safety of low and ultralow-dose rituximab in NMOSD. Methods We conducted a retrospective analysis of NMOSD patients treated with rituximab at two Chinese tertiary hospitals. Patients
-
SARS-CoV-2 induces inflammation and intracranial infection through the olfactory epithelium-olfactory bulb pathway in non-human primates J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-08 Shino Shimizu, Misako Nakayama, Cong Thanh Nguyen, Hirohito Ishigaki, Yoshinori Kitagawa, Fumihiko Yasui, Yoshiki Yagi, Tomoe Kusayanagi, Michinori Kohara, Yasushi Itoh, Ichiro Tojima, Hideaki Kouzaki, Takeshi Shimizu
We examined the histopathological changes in the olfactory mucosa of cynomolgus and rhesus macaque models of SARS-CoV-2 infection. SARS-CoV-2 infection induced severe inflammatory changes in the olfactory mucosa. A major histocompatibility complex (MHC) class II molecule, HLA-DR was expressed in macrophage and supporting cells, and melanocytes were increased in olfactory mucosa. Supporting cells and
-
Peripheral blood regulatory B and T cells are decreased in patients with focal epilepsy J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-08 Elif Sanli, Nermin Gorkem Sirin, Cem Ismail Kucukali, Betul Baykan, Canan Aysel Ulusoy, Nerses Bebek, Vuslat Yilmaz, Erdem Tuzun
Patients with focal epilepsy of unknown cause (FEoUC) may display T cell infiltration in post-surgery brain specimens and increased serum levels of pro-inflammatory cytokines produced by B and T cells, indicating potential involvement of adaptive immunity. Our study aimed to investigate the peripheral blood distribution of B and T cell subgroups to find clues supporting the distinct organization of
-
Dysregulated autotaxin expression by T cells in multiple sclerosis J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-03 Cora L. Petersen-Cherubini, Yue Liu, Joshua L. Deffenbaugh, Shawn P. Murphy, Matthew Xin, Christina N. Rau, Yuhong Yang, Amy E. Lovett-Racke
-
Inherited chromosomally-integrated human herpes virus 6 confounding test results in a patient with myelitis and optic neuritis – A case report J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-04 Zhibin Tan, Yvonne May Fen Chia, Xiaomin Mu, You-Jiang Tan
A case of the ‘perfect storm’ of myelin oligodendrocyte glycoprotein (MOG) antibody-mediated myelitis, human herpesvirus 6 (HHV-6) reactivation, and COVID-19 infection was reported in 2021. This article reports a case of a similarly observed clinical triad, but with a different conclusion and explanation supported by laboratory test results and evidence from our literature review.
-
Early-stage volume losses in the corpus callosum and thalamus predict the progression of brain atrophy in patients with multiple sclerosis J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-01 Juichi Fujimori, Ichiro Nakashima
Background A method that can be used in the early stage of multiple sclerosis (MS) to predict the progression of brain volume loss (BVL) has not been fully established. Methods To develop a method of predicting progressive BVL in patients with MS (pwMS), eighty-two consecutive Japanese pwMS—with either relapsing-remitting MS (86%) or secondary progressive MS (14%)—and 41 healthy controls were included
-
Polygalasaponin F ameliorates middle cerebral artery occlusion-induced focal ischemia / reperfusion injury in rats through inhibiting TXNIP/NLRP3 signaling pathway J. Neuroimmunol. (IF 3.3) Pub Date : 2024-01-04 Yao Chen, Hanzhou Li, Yan Yang, Lei Feng, Ling Yang, Jie Zhao, Xiaochi Xin, Shuquan Lv, Xixing Fang, Weibo Wen, Youxiang Cui, Huantian Cui
-
"Lipopolysaccharide-induced animal models for neuroinflammation – An overview." J. Neuroimmunol. (IF 3.3) Pub Date : 2023-12-31 Ana Alexandra Flores da Silva, Mariana Bernardo Fiadeiro, Liliana Inácio Bernardino, Carla Sofia Pais Fonseca, Graça Maria Fernandes Baltazar, Ana Clara Braz Cristóvão
-
Increased production of inflammatory cytokines by circulating monocytes in mesial temporal lobe epilepsy: A possible role in drug resistance J. Neuroimmunol. (IF 3.3) Pub Date : 2023-12-23 C. Milano, M. Montali, S. Barachini, I.S. Burzi, F. Pratesi, L. Petrozzi, L. Chico, R. Morganti, G. Gambino, L. Rossi, R. Ceravolo, G. Siciliano, P. Migliorini, I. Petrini, C. Pizzanelli
-
Electroconvulsive therapy for catatonia in anti-NMDA receptor encephalitis: A case series J. Neuroimmunol. (IF 3.3) Pub Date : 2023-12-22 Lara Wadi, Vishal Mandge
Background Anti-NMDAR encephalitis is the most common cause of immune-mediated catatonia. Case series Three females presented with neuropsychiatric symptoms and were empirically treated with first-line immunotherapy and ovarian teratoma resection for suspected autoimmune encephalitis, preceding diagnostic confirmation via NMDAR antibody positivity. They required escalating large doses of benzodiazepines
-
Biomarkers of disability worsening in inactive primary progressive multiple sclerosis J. Neuroimmunol. (IF 3.3) Pub Date : 2023-12-23 Maria-Elizabeth Baeva, Isabelle Tottenham, Marcus Koch, Carlos Camara-Lemarroy
Objective To investigate serum biomarkers of progression in inactive primary progressive multiple sclerosis (PPMS). Methods We measured protein biomarkers (growth differentiation factor-15 (GDF-15), dickkopf-1 (DKK-1), neuron specific enolase (NSE) and cathepsin-D) in serum samples from 39 patients with inactive PPMS included in a clinical trial enrolling people with PPMS (clinicaltrials.gov identifier
-
Neuropsychological profiles comparison between Multiple Sclerosis patients and Multiple Sclerosis patients with overlapping features of Systemic Lupus Erythematosus J. Neuroimmunol. (IF 3.3) Pub Date : 2023-12-21 Konstantina Stavrogianni, Dimitrios K. Kitsos, Vasileios Giannopapas, Athanasios K. Chasiotis, Niki Christouli, Panagiotis G. Paraskevas, Christina Zompola, Georgios Tsivgoulis, George P. Paraskevas, Sotirios Giannopoulos
Aim Multiple sclerosis (MS) and Systemic Lupus Erythematosus (SLE) are autoimmune disorders that may lead to cognitive impairment. This study aimed to compare the neuropsychological profiles of patients with MS, and MS and coexisting SLE features. Methods We included a total of 90 participants, divided into 3 groups: 30 patients with clinically definite relapsing remitting MS, 30 with coexisting MS
-
Rs1800629 polymorphism in TNF-alpha is associated with the susceptibility and initial short-term glucocorticoids efficacy in myasthenia gravis patients J. Neuroimmunol. (IF 3.3) Pub Date : 2023-12-20 Hong-Yan Li, Meng Xia, Min Song, Yanchen Xie, Qi Wang, Yao-Xian Yue, Hai-Feng Li
Tumor necrosis factor-alpha (TNF-α) is a potent pro-inflammatory agent involved in various autoimmune and inflammatory diseases including myasthenia gravis (MG). In this study, we enrolled 409 adult MG patients and 487 healthy individuals to investigate the association between TNF-α polymorphism and MG. We found the rs1800629 A allele frequency was significantly higher in the MG group than in the control
-
YTHDF2 alleviates microglia activation via promoting circHIPK2 degradation J. Neuroimmunol. (IF 3.3) Pub Date : 2023-12-19 Rongrong Huang, Ming Sun, Weiwei Wang, Xiaoyu Yu, Fan Liu
-
Exosome-transmitted ANGPTL1 suppresses angiogenesis in glioblastoma by inhibiting the VEGFA/VEGFR2/Akt/eNOS pathway J. Neuroimmunol. (IF 3.3) Pub Date : 2023-12-15 Dong Wang, Huichen Li, Tianxiang Zeng, Qiang Chen, Weilong Huang, Yujing Huang, Yuqing Liao, Qiuhua Jiang
Objective Glioblastoma (GBM) is a highly vascularized malignancy that relies on new vessel generation, and thus targeting angiogenesis has been a promising anti-GBM approach. ANGPTL1 is well-known for its anti-angiogenic property; nevertheless, its role in GBM is yet to be explored. Recently, the crucial role of exosomes (Exos) as intercellular communication mediators has gained prominence in GBM therapy
-
Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed meninges in a chronic model of central nervous system autoimmunity J. Neuroimmunol. (IF 3.3) Pub Date : 2023-12-15 Yodit Tesfagiorgis, Eden A. Kemal, Heather C. Craig, Kate A. Parham, Steven M. Kerfoot
Anti-CD20 B cell depleting therapies have demonstrated that B cells are important drivers of disease progress in Multiple Sclerosis, although the pathogenic mechanisms are not well understood. A population of B cells accumulates in the inflamed meninges in MS and also some chronic animal models of disease, typically adjacent to demyelinating lesions. The role of these meningeal B cells in disease is
-
Clinical features and prognosis of Tibetan patients with neuromyelitis optica spectrum disorder are different from those of Han Chinese patients J. Neuroimmunol. (IF 3.3) Pub Date : 2023-12-13 Wenqin Luo, Xiaofei Wang, Lingyao Kong, Hongxi Chen, Ziyan Shi, Hongyu Zhou
We compared the prognosis of Tibetan and Han Chinese patients with neuromyelitis optica spectrum disorder (NMOSD). The Expanded Disability Status Scale (EDSS) score at each attack, response to immunosuppressive therapy, risk of first relapse, severe attack, visual disability, motor disability, and total risk of disability were compared between Tibetan and Han Chinese patients. Tibetan patients showed
-
Sjogren's syndrome meets Meige's syndrome J. Neuroimmunol. (IF 3.3) Pub Date : 2023-12-10 Xuemei Li, Li Su, Yi Zhao
This report details a rare case where a patient simultaneously suffered from Sjogren's syndrome (SS) and Meige's syndrome (MS). SS, an autoimmune disorder, and MS, a rare neurological condition characterized by involuntary eyelid closure, presented in a 73-year-old male. The patient had been experiencing dry eye symptoms for the past 5 years, with the onset of eyelid spasms and tetanic eye closure
-
Cadmium exposure exacerbates immunological abnormalities in a BTBR T+ Itpr3tf/J autistic mouse model by upregulating inflammatory mediators in CD45R-expressing cells J. Neuroimmunol. (IF 3.3) Pub Date : 2023-12-03 Thamer H. Albekairi, Mohammed M. Alanazi, Mushtaq A. Ansari, Ahmed Nadeem, Sabry M. Attia, Saleh A. Bakheet, Haneen A. Al-Mazroua, Abdullah A. Aldossari, Taghreed N. Almanaa, Mohammad Y. Alwetaid, Mohammed Alqinyah, Hajar O. Alnefaie, Sheikh F. Ahmad
Autism spectrum disorder (ASD) is a neurodevelopmental illness characterized by behavior, learning, communication, and social interaction abnormalities in various situations. Individuals with impairments usually exhibit restricted and repetitive actions. The actual cause of ASD is yet unknown. It is believed, however, that a mix of genetic and environmental factors may play a role in its development
-
Sleep deprivation aggravates lipopolysaccharide-induced anxiety, depression and cognitive impairment: The role of pro-inflammatory cytokines and synaptic plasticity-associated proteins J. Neuroimmunol. (IF 3.3) Pub Date : 2023-12-04 Yue-Ming Zhang, Ru-Meng Wei, Yi-Zhou Feng, Kai-Xuan Zhang, Yi-Jun Ge, Xiao-Yi Kong, Xue-Yan Li, Gui-Hai Chen
Growing evidence indicates that neuroinflammation plays a critical role in anxiety, depression, and cognitive impairment. Sleep loss disrupts the host's immune balance and increases neuroinflammation. This study explored whether chronic sleep deprivation aggravates lipopolysaccharide-induced anxiety, depression, and cognitive impairment and assessed the underlying mechanisms. Lipopolysaccharide (250 μg/kg)
-
Adult-onset neurodegeneration in XMEN disease J. Neuroimmunol. (IF 3.3) Pub Date : 2023-11-24 Daniel Benavides, Anusha Ebrahim, Juan C. Ravell, Michael Lenardo, William A. Gahl, Camilo Toro
Background XMEN (X-linked immunodeficiency with magnesium defect, Epstein-Barr virus (EBV), and N-linked glycosylation defect) disease results from loss-of-function mutations in MAGT1, a protein that serves as a magnesium transporter and a subunit of the oligosaccharyltransferase (OST) complex. MAGT1 deficiency disrupts N-linked glycosylation, a critical regulator of immune function. XMEN results in
-
Progressive multifocal leukoencephalopathy secondary to idiopathic CD4 lymphocytopenia treated with pembrolizumab J. Neuroimmunol. (IF 3.3) Pub Date : 2023-11-18 Kyriakoula Varmpompiti, Andrew J. Westwood, Aaron Ben-Joseph, Naomi Sibtain, Mohammad A.A. Ibrahim, Biba Stanton, Mark Zuckerman, Robert Hadden, Laura Mantoan Ritter
Background Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease due to a lytic infection of oligodendrocytes caused by John Cunningham polyoma virus (JCV) infection. Idiopathic CD4+ T-cell lymphocytopenia (ICL) is a very rare cause of PML. Methods We present an individual with PML secondary to ICL treated with 3 doses of pembrolizumab, a Programmed-Death-1 Immune Checkpoint
-
Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection J. Neuroimmunol. (IF 3.3) Pub Date : 2023-11-21 Ying Chen, Wenbin Wan, Xiaoying Yao, Yangtai Guan
Patients with both myasthenia gravis (MG) and SARS-CoV-2 infection face treatment challenges due to potential drug interactions. One common immunosuppressant for MG, Tacrolimus, is primarily metabolized by the cytochrome P450. However, Paxlovid, an antiviral medication, inhibits cytochrome P450 activity, which can lead to increased Tacrolimus levels and potential toxicity when the two drugs are combined
-
case of autoimmune GFAP astrocytopathy with eosinophils in the cerebrospinal fluid J. Neuroimmunol. (IF 3.3) Pub Date : 2023-11-19 Mallory C. Lowe, Kelli M. Money, Elizabeth Matthews, Daniel M. Pastula, Amanda L. Piquet
Cerebrospinal fluid (CSF) eosinophilia is associated with a narrow differential, primarily including parasitic and fungal infections, neoplasm, and chemical meningitis. It has rarely been reported in neuroinflammatory conditions including as a finding of CSF cytology in two autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy cases. Here we describe a case of autoimmune GFAP astrocytopathy
-
Effect of the sEH inhibitor AUDA on arachidonic acid metabolism and NF-κB signaling of rats with postpartum depression-like behavior J. Neuroimmunol. (IF 3.3) Pub Date : 2023-11-22 Liqin Duan, Linhong Song, Chao Qiu, Jingya Li
Objective To investigate whether sEH inhibitor AUDA can mitigate postpartum depression (PPD)-like symptoms in the rat model and regulate the AA/NF-κB pathway to suppress the inflammatory response in the prefrontal lobes of PPD rats. Methods Five groups of Sprague Dawley rats were used: normal, sham operated, PPD model, AUDA, and paroxetine hydrochloride. During the 21-day treatment period, animals
-
Hydroxyurea interaction with α7 nicotinic acetylcholine receptor can underlie its therapeutic efficacy upon COVID-19 J. Neuroimmunol. (IF 3.3) Pub Date : 2023-11-21 Olena Lykhmus, Olena Kalashnyk, Raymond Sullivan, Maryna Skok
-
Systemic treatment with a selective TNFR2 agonist alters the central and peripheral immune responses and transiently improves functional outcome after experimental ischemic stroke J. Neuroimmunol. (IF 3.3) Pub Date : 2023-11-17 Estrid Thougaard, Pernille Vinther Nielsen, Amalie Forsberg, Victoria Phuong, Aitana Martínez Velasco, Agnieszka Wlodarczyk, Harald Wajant, Isabell Lang, Jens D. Mikkelsen, Bettina Hjelm Clausen, Roberta Brambilla, Kate Lykke Lambertsen
-
Voluntary wheel running from early adolescence reduces disease progression, and anxiety- and depression-related symptoms in an adult male mouse model of rheumatoid arthritis J. Neuroimmunol. (IF 3.3) Pub Date : 2023-11-14 Sheida Payamipour, Maghsoud Peeri, Mohammad Ali Azarbayjani, Forouzan Fattahi Masrour
Rheumatoid arthritis (RA) is a multifactorial autoimmune disease that progressively destroys synovial joints and leads to chronic systemic inflammation. This autoimmune disorder is associated with increased anxiety- and depression-related symptoms, which reduces quality of life. Clinical and experimental evidence suggests that higher physical activity from early adolescence may prevent chronic diseases
-
Circulating levels of inflammatory biomarkers in Huntington's disease: A systematic review and meta-analysis J. Neuroimmunol. (IF 3.3) Pub Date : 2023-11-13 Alireza Soltani Khaboushan, Aysan Moeinafshar, Mohammad Hamed Ersi, Antonio L. Teixeira, Masoumeh Majidi Zolbin, Abdol-Mohammad Kajbafzadeh
Background Huntington's disease (HD) is an autosomal dominant disease caused by an abnormally high number of CAG repeats at the huntingtin-encoding gene, HTT. This genetic alteration results in the expression of a mutant form of the protein (mHTT) and the formation of intracellular aggregates, inducing an inflammatory state within the affected areas. This dysfunction of inflammatory response leads
-
Weight-drop model as a valuable tool to study potential neurobiological processes underlying behavioral and cognitive changes secondary to mild traumatic brain injury J. Neuroimmunol. (IF 3.3) Pub Date : 2023-11-07 Caroline Amaral Machado, Bruna da Silva Oliveira, Thomaz Lüscher Dias, João Luís Vieira Monteiro de Barros, Gabriel Moreira Félix Ferreira, Thiago Macedo Cordeiro, Victor Feracin, Cristian Henrique Alexandre, Larissa Katharina Sabino Abreu, Walison Nunes da Silva, Brener Cunha Carvalho, Heliana de Barros Fernandes, Érica Leandro Marciano Vieira, Pollyana Ribeiro Castro, Rodrigo Novaes Ferreira, Lucas
The pathophysiology of post-traumatic brain injury (TBI) behavioral and cognitive changes is not fully understood, especially in its mild presentation. We designed a weight drop TBI model in mice to investigate the role of neuroinflammation in behavioral and cognitive sequelae following mild TBI. C57BL/6 mice displayed depressive-like behavior at 72 h after mild TBI compared with controls, as indicated